College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
Cells. 2023 Jan 19;12(3):367. doi: 10.3390/cells12030367.
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with different molecular subtypes. Although progress has been made, the identification of TNBC subtype-associated biomarkers is still hindered by traditional RNA-seq or array technologies, since bulk data detected by them usually have some non-disease tissue samples, or they are confined to measure the averaged properties of whole tissues. To overcome these constraints and discover TNBC subtype-specific prognosis signatures (TSPSigs), we proposed a single-cell RNA-seq-based bioinformatics approach for identifying TSPSigs. Notably, the TSPSigs we developed mostly were found to be disease-related and involved in cancer development through investigating their enrichment analysis results. In addition, the prognostic power of TSPSigs was successfully confirmed in four independent validation datasets. The multivariate analysis results showed that TSPSigs in two TNBC subtypes-BL1 and LAR, were two independent prognostic factors. Further, analysis results of the TNBC cell lines revealed that the TSPSigs expressions and drug sensitivities had significant associations. Based on the preceding data, we concluded that TSPSigs could be exploited as novel candidate prognostic markers for TNBC patients and applied to individualized treatment in the future.
三阴性乳腺癌(TNBC)是一种高度异质性的疾病,具有不同的分子亚型。尽管已经取得了进展,但由于传统的 RNA-seq 或阵列技术检测的是批量数据,其中通常包含一些非疾病组织样本,或者它们仅限于测量整个组织的平均特性,因此,识别与 TNBC 亚型相关的生物标志物仍然受到阻碍。为了克服这些限制并发现 TNBC 亚型特异性预后特征(TSPSigs),我们提出了一种基于单细胞 RNA-seq 的生物信息学方法来识别 TSPSigs。值得注意的是,通过研究其富集分析结果,我们开发的 TSPSigs 主要被发现与疾病相关,并参与癌症的发展。此外,在四个独立的验证数据集中成功证实了 TSPSigs 的预后能力。多变量分析结果表明,在两种 TNBC 亚型-BL1 和 LAR 中,TSPSigs 是两个独立的预后因素。此外,对 TNBC 细胞系的分析结果表明,TSPSigs 的表达和药物敏感性之间存在显著关联。基于上述数据,我们得出结论,TSPSigs 可以作为 TNBC 患者的新型候选预后标志物,并在未来应用于个体化治疗。